Back A A A Font Size Receive E-mail Alerts Press Releases

FOXTROT™ NC PTCA Balloon Catheter Gains Regulatory Approval in Argentina


Buenos Aires, Argentina – FOXTROT™ NC PTCA Balloon Catheter, in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), recently received regulatory approval from the ANMAT, Argentina's National Administration of Drugs, Foods and Medical Devices. Previously, the product had received CE mark and gained approvals from US Food and Drug Administration, China Food and Drug Administration, Japan's Ministry of Health, Labour and Welfare, as well as regulatory authorities in the Philippines, Thailand, Brazil, Mexico and etc.
FOXTROT™ NC PTCA Balloon Catheter is a rapid exchange percutaneous transluminal coronary angioplasty catheter. It is indicated for balloon angioplasty or assisting with balloon expandable stents implantation in pre-dilation as well as post-dilation. The design is an integrated shaft system with a non-compliant balloon near the distal tip. The balloon is designed to provide an inflatable segment of rated diameter and length at recommended pressures. Two radiopaque markers aid in positioning the balloon catheter under fluoroscopy during the procedure. The device features high rated burst pressure, low compliance, and excellent pushability, trackability and crossability.
Aside from FOXTROT™ NC PTCA Balloon Catheter, other coronary interventional products such as Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), FOXTROT™ PRO PTCA Balloon Dilatation Catheter, and Firefighter™ PTCA Balloon Catheter, also gained regulatory approval in Argentina. The official entry of FOXTROT™ NC PTCA Balloon Catheter into the Argentina market will further diversify the portfolio of MicroPort®'s coronary products to provide more comprehensive solutions for patients in Argentina and even the whole South America.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:Three Projects of MicroPort® Granted 2015-2016 Pudong Science and Technology Awards
[Next]:MicroPort® NeuroTech Attends 17th OCIN